Trials / Active Not Recruiting
Active Not RecruitingNCT06874725
Latent Tuberculosis in Type 2 Diabetes
Directly Observed Preventive Therapy (DOPT) for Latent Tuberculosis Infection Patients With Poorly Controlled Diabetes Mellitus
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 552 (actual)
- Sponsor
- Taichung Veterans General Hospital · Academic / Other
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.
Detailed description
Poor control of diabetes mellitus (DM) increases active tuberculosis (TB) risk. Understanding risk factors for latent TB infection (LTBI) in this population is crucial for policy making. Under a collaborative multidisciplinary team consisting of endocrinologists and pulmonologists, patients with poorly controlled DM were enrolled; these patients underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifapentine and Isoniazid for 3 months | tuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP) |
| DRUG | Isoniazid (INH) daily for 9 months | tuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H) |
Timeline
- Start date
- 2018-04-18
- Primary completion
- 2024-04-30
- Completion
- 2025-04-18
- First posted
- 2025-03-13
- Last updated
- 2025-03-13
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06874725. Inclusion in this directory is not an endorsement.